Potential clinical applications of multi-functional milk proteins and peptides in cancer management

Current Medicinal Chemistry

Volumn 21, Issue 21, 2014, Pages 2424-2437

  Chen, H Y F ^a   Mollstedt, O ^a   Tsai, Men Hwei ^a   Kreider, R B ^b  

^a Ambryx Biotechnology Inc   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Apoptosis; Cancer; Clinical nutrition; Immunomodulatory; Milk; Peptides; Therapeutics

Indexed keywords

ALPHA LACTALBUMIN; CASEIN; LACTOFERRICIN; LACTOFERRIN; MILK PROTEIN; PEPTIDE DERIVATIVE; RECOMBINANT PROTEIN; ANTINEOPLASTIC AGENT; PEPTIDE;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER THERAPY; CELL PROLIFERATION; COLOSTRUM; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; METASTASIS INHIBITION; NONHUMAN; NUTRITION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; ANIMAL; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MILK PROTEINS; NEOPLASMS; PEPTIDES;

EID: 84901951020     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140205135739     Document Type: Article

References (170)

1. Dranoff, G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer, 2004, 4 (1), 11-22.
2. Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 2011, 331 (6024), 1565-1570.
3. Chow, M.T.; Moller, A.; Smyth, M.J. Inflammation and immune surveillance in cancer. Semin. Cancer Biol., 2012, 22 (1), 23-32.
4. Coussens, L.M.; Zitvogel, L.; Palucka, A.K. Neutralizing tumorpromoting chronic inflammation: a magic bullet? Science, 2013, 339 (6117), 286-291.
5. Finn, O.J. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann. Oncol., 2012, 23 Suppl 8, viii6-viii9.
6. Lampe, J.W. Dairy products and cancer. J. Am. Coll. Nutr., 2011, 30 (5 Suppl 1), 464S-470S.
7. Torfadottir, J.E.; Steingrimsdottir, L.; Mucci, L.; Aspelund, T.; Kasperzyk, J.L.; Olafsson, O.; Fall, K.; Tryggvadottir, L.; Harris, T.B.; Launer, L.; Jonsson, E.; Tulinius, H.; Stampfer, M.; Adami, H.O.; Gudnason, V.; Valdimarsdottir, U.A. Milk intake in early life and risk of advanced prostate cancer. Am. J. Epidemiol., 2012, 175 (2), 144-153.
8. Dong, J.Y.; Zhang, L.; He, K.; Qin, L.Q. Dairy consumption and risk of breast cancer: a meta-analysis of prospective cohort studies. Breast Cancer Res. Treat., 2011, 127 (1), 23-31.
9. Gill, H.S.; Doull, F.; Rutherfurd, K.J.; Cross, M.L. Immunoregulatory peptides in bovine milk. Br. J. Nutr., 2000, 84 Suppl 1, S111-S117.
10. Blum, J.W.; Baumrucker, C.R. Insulin-like growth factors (IGFs), IGF binding proteins, and other endocrine factors in milk: role in the newborn. Adv. Exp. Med. Biol., 2008, 606, 397-422.
11. Melnik, B.C.; John, S.M.; Carrera-Bastos, P.; Cordain, L. The impact of cow's milk-mediated mTORC1-signaling in the initiation and progression of prostate cancer. Nutr. Metab. (Lond.), 2012, 9 (1), 74.
12. Wahdan-Alaswad, R.S.; Song, K.; Krebs, T.L.; Shola, D.T.; Gomez, J.A.; Matsuyama, S.; Danielpour, D. Insulin-like growth factor I suppresses bone morphogenetic protein signaling in prostate cancer cells by activating mTOR signaling. Cancer Res., 2010, 70 (22), 9106-9117.
13. Korhonen, H.; Pihlanto, A. Technological options for the production of health-promoting proteins and peptides derived from milk and colostrum. Curr. Pharm. Des., 2007, 13 (8), 829-843.
14. Muro Urista, C.; Alvarez Fernandez, R.; Riera Rodriguez, F.; Arana Cuenca, A.; Tellez Jurado, A. Review: Production and functionality of active peptides from milk. Food Sci. Technol. Int., 2011, 17 (4), 293-317.
15. Gustafsson, L.; Leijonhufvud, I.; Aronsson, A.; Mossberg, A.K.; Svanborg, C. Treatment of skin papillomas with topical alphalactalbumin-oleic acid. N. Engl. J. Med., 2004, 350 (26), 2663-2672.
16. Mossberg, A.K.; Wullt, B.; Gustafsson, L.; Mansson, W.; Ljunggren, E.; Svanborg, C. Bladder cancers respond to intravesical instillation of HAMLET (human alpha-lactalbumin made lethal to tumor cells). Int. J. Cancer, 2007, 121 (6), 1352-1359.
17. Kelly, R.J.; Giaccone, G. The role of talactoferrin alpha in the treatment of non-small cell lung cancer. Expert Opin. Biol. Ther., 2010, 10 (9), 1379-1386.
18. Parikh, P.M.; Vaid, A.; Advani, S.H.; Digumarti, R.; Madhavan, J.; Nag, S.; Bapna, A.; Sekhon, J.S.; Patil, S.; Ismail, P.M.; Wang, Y.; Varadhachary, A.; Zhu, J.; Malik, R. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J. Clin. Oncol., 2011, 29 (31), 4129-4136.
19. Jonasch, E.; Stadler, W.M.; Bukowski, R.M.; Hayes, T.G.; Varadhachary, A.; Malik, R.; Figlin, R.A.; Srinivas, S. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer, 2008, 113 (1), 72-77.
20. Clare, D.A.; Swaisgood, H.E. Bioactive milk peptides: a prospectus. J. Dairy Sci., 2000, 83 (6), 1187-1195.
21. Meisel, H. Multifunctional peptides encrypted in milk proteins. Biofactors, 2004, 21 (1-4), 55-61.
22. Lopez-Exposito, I.; Recio, I. Protective effect of milk peptides: antibacterial and antitumor properties. Adv. Exp. Med. Biol., 2008, 606, 271-293.
23. Meisel, H. Biochemical properties of peptides encrypted in bovine milk proteins. Curr. Med. Chem., 2005, 12 (16), 1905-1919.
24. Pepe, G.; Tenore, G.C.; Mastrocinque, R.; Stusio, P.; Campiglia, P. Potential anticarcinogenic peptides from bovine milk. J. Amino Acids, 2013, 2013, 939804.
25. Pihlanto, A. Antioxidative peptides derived from milk proteins. Int. Dairy J., 2006, 16 (11), 1306-1314.
26. Krissansen, G.W. Emerging health properties of whey proteins and their clinical implications. J. Am. Coll. Nutr., 2007, 26 (6), 713S-723S.
27. Meisel, H.; Bockelmann, W. Bioactive peptides encrypted in milk proteins: proteolytic activation and thropho-functional properties. Antonie Van Leeuwenhoek, 1999, 76 (1-4), 207-215.
28. Autelitano, D.J.; Rajic, A.; Smith, A.I.; Berndt, M.C.; Ilag, L.L.; Vadas, M. The cryptome: a subset of the proteome, comprising cryptic peptides with distinct bioactivities. Drug Discov. Today, 2006, 11 (7-8), 306-314.
29. Ebringer, L.; Ferencik, M.; Krajcovic, J. Beneficial health effects of milk and fermented dairy products - review. Folia Microbiol. (Praha), 2008, 53 (5), 378-394. (Pubitemid 352840225)
30. Hannu, K.; Anne, P.Ä.l. In Handbook of Functional Dairy Products; CRC Press, 2003.
31. Perdigon, G.; Fuller, R.; Raya, R. Lactic acid bacteria and their effect on the immune system. Curr. Issues Intest. Microbiol., 2001, 2 (1), 27-42.
32. Shiby, V.K.; Mishra, H.N. Fermented milks and milk products as functional foods - a review. Crit. Rev. Food Sci. Nutr., 2013, 53 (5), 482-496.
33. Beermann, C.; Hartung, J. Physiological properties of milk ingredients released by fermentation. Food Funct., 2013, 4 (2), 185-199.
34. Kumari, A.; Catanzaro, R.; Marotta, F. Clinical importance of lactic acid bacteria: a short review. Acta Biomed., 2011, 82 (3), 177-180.
35. Kim, J.E.; Kim, J.Y.; Lee, K.W.; Lee, H.J. Cancer chemopreventive effects of lactic acid bacteria. J. Microbiol. Biotechnol., 2007, 17 (8), 1227-1235.
36. Vinderola, G.; Matar, C.; Perdigon, G. Milk fermentation products of L. helveticus R389 activate calcineurin as a signal to promote gut mucosal immunity. BMC Immunol., 2007, 8, 19.
37. Leblanc, J.; Fliss, I.; Matar, C. Induction of a humoral immune response following an Escherichia coli O157:H7 infection with an immunomodulatory peptidic fraction derived from Lactobacillus helveticus-fermented milk. Clin. Diagn. Lab. Immunol., 2004, 11 (6), 1171-1181.
38. LeBlanc, J.G.; Matar, C.; Valdez, J.C.; LeBlanc, J.; Perdigon, G. Immunomodulating effects of peptidic fractions issued from milk fermented with Lactobacillus helveticus. J. Dairy Sci., 2002, 85 (11), 2733-2742.
39. Bastian, E.D.; Brown, R.J. Plasmin in milk and dairy products: an update. Int. Dairy J., 1996, 6 (5), 435-457.
40. Stefanutti, E. Angiostatin like peptides in milk: potential development for dairy products capable of cancer prevention. Master Thesis, California Polytechnic State University, San Luis Obispo, March 2011.
41. O'Reilly, M.S.; Holmgren, L.; Shing, Y.; Chen, C.; Rosenthal, R.A.; Moses, M.; Lane, W.S.; Cao, Y.; Sage, E.H.; Folkman, J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 1994, 79 (2), 315-328.
42. Cao, Y. Therapeutic potentials of angiostatin in the treatment of cancer. Haematologica, 1999, 84 (7), 643-650.
43. Dell'Eva, R.; Pfeffer, U.; Indraccolo, S.; Albini, A.; Noonan, D. Inhibition of tumor angiogenesis by angiostatin: from recombinant protein to gene therapy. Endothelium, 2002, 9 (1), 3-10.
44. Kurup, A.; Lin, C.; Murry, D.J.; Dobrolecki, L.; Estes, D.; Yiannoutsos, C.T.; Mariano, L.; Sidor, C.; Hickey, R.; Hanna, N. Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann. Oncol., 2006, 17 (1), 97-103.
45. Meisel, H.; FitzGerald, R.J. Biofunctional peptides from milk proteins: mineral binding and cytomodulatory effects. Curr. Pharm. Des., 2003, 9 (16), 1289-1295.
46. Perego, S.; Cosentino, S.; Fiorilli, A.; Tettamanti, G.; Ferraretto, A. Casein phosphopeptides modulate proliferation and apoptosis in HT-29 cell line through their interaction with voltage-operated Ltype calcium channels. J. Nutr. Biochem., 2012, 23 (7), 808-816.
47. De Simone, C.; Ferranti, P.; Picariello, G.; Scognamiglio, I.; Dicitore, A.; Addeo, F.; Chianese, L.; Stiuso, P. Peptides from water buffalo cheese whey induced senescence cell death via ceramide secretion in human colon adenocarcinoma cell line. Mol. Nutr. Food Res., 2011, 55 (2), 229-238.
48. De Simone, C.; Picariello, G.; Mamone, G.; Stiuso, P.; Dicitore, A.; Vanacore, D.; Chianese, L.; Addeo, F.; Ferranti, P. Characterisation and cytomodulatory properties of peptides from Mozzarella di Bufala Campana cheese whey. J. Pept. Sci., 2009, 15 (3), 251-258.
49. Hatzoglou, A.; Bakogeorgou, E.; Hatzoglou, C.; Martin, P.M.; Castanas, E. Antiproliferative and receptor binding properties of alpha-and beta-casomorphins in the T47D human breast cancer cell line. Eur. J. Pharmacol., 1996, 310 (2-3), 217-223.
50. Kampa, M.; Bakogeorgou, E.; Hatzoglou, A.; Damianaki, A.; Martin, P.M.; Castanas, E. Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors. Eur. J. Pharmacol., 1997, 335 (2-3), 255-265.
51. Kreider, R.B.; Iosia, M.; Cooke, M.; Hudson, G.; Rasmussen, C.; Chen, H.; Mollstedt, O.; Tsai, M.H. Bioactive properties and clinical safety of a novel milk protein peptide. Nutr. J., 2011, 10, 99.
52. Chua, W.; Charles, K.A.; Baracos, V.E.; Clarke, S.J. Neutrophil/ lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br. J. Cancer, 2011, 104 (8), 1288-1295.
53. Azab, B.; Bhatt, V.R.; Phookan, J.; Murukutla, S.; Kohn, N.; Terjanian, T.; Widmann, W.D. Usefulness of the neutrophil-tolymphocyte ratio in predicting short-and long-term mortality in breast cancer patients. Ann. Surg. Oncol., 2012, 19 (1), 217-224.
54. Sharaiha, R.Z.; Halazun, K.J.; Mirza, F.; Port, J.L.; Lee, P.C.; Neugut, A.I.; Altorki, N.K.; Abrams, J.A. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann. Surg. Oncol., 2011, 18 (12), 3362-3369.
55. Ogilvie GK, C.H., Mollstedt O, Proulx DM, Van Horn L, Price MD, Tsai MH In American College of Veterinary Internal Medicine Forum. McFarlane D, T.J., Ed.; Omnipress: Denver, Colorado, 2011, p 410.
56. Adessi, C.; Soto, C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem., 2002, 9 (9), 963-978.
57. Mason, J.M. Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention. Future Med. Chem., 2010, 2 (12), 1813-1822.
58. Gibbons, J.A.; Kanwar, R.K.; Kanwar, J.R. Lactoferrin and cancer in different cancer models. Front. Biosci. (Schol. Ed.), 2011, 3, 1080-1088.
59. Ward, P.P.; Paz, E.; Conneely, O.M. Multifunctional roles of lactoferrin: a critical overview. Cell. Mol. Life Sci., 2005, 62 (22), 2540-2548.
60. Tsuda, H.; Kozu, T.; Iinuma, G.; Ohashi, Y.; Saito, Y.; Saito, D.; Akasu, T.; Alexander, D.B.; Futakuchi, M.; Fukamachi, K.; Xu, J.; Kakizoe, T.; Iigo, M. Cancer prevention by bovine lactoferrin: from animal studies to human trial. Biometals, 2010, 23 (3), 399-409.
61. Tomita, M.; Wakabayashi, H.; Shin, K.; Yamauchi, K.; Yaeshima, T.; Iwatsuki, K. Twenty-five years of research on bovine lactoferrin applications. Biochimie, 2009, 91 (1), 52-57.
62. Yoo, Y.C.; Watanabe, S.; Watanabe, R.; Hata, K.; Shimazaki, K.; Azuma, I. Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn. J. Cancer Res., 1997, 88 (2), 184-190.
63. Artym, J.; Zimecki, M.; Kruzel, M. Normalization of peripheral blood cell composition by lactoferrin in cyclophosphamide-treated mice. Med. Sci. Monit., 2004, 10 (3), BR84-89.
64. Tsuda, H.; Sekine, K.; Fujita, K.; Ligo, M. Cancer prevention by bovine lactoferrin and underlying mechanisms - a review of experimental and clinical studies. Biochem. Cell Biol., 2002, 80 (1), 131-136.
65. Iigo, M.; Alexander, D.B.; Long, N.; Xu, J.; Fukamachi, K.; Futakuchi, M.; Takase, M.; Tsuda, H. Anticarcinogenesis pathways activated by bovine lactoferrin in the murine small intestine. Biochimie, 2009, 91 (1), 86-101.
66. Shimizu, K.; Matsuzawa, H.; Okada, K.; Tazume, S.; Dosako, S.; Kawasaki, Y.; Hashimoto, K.; Koga, Y. Lactoferrin-mediated protection of the host from murine cytomegalovirus infection by a Tcell-dependent augmentation of natural killer cell activity. Arch. Virol., 1996, 141 (10), 1875-1889.
67. Beljaars, L.; van der Strate, B.W.; Bakker, H.I.; Reker-Smit, C.; van Loenen-Weemaes, A.M.; Wiegmans, F.C.; Harmsen, M.C.; Molema, G.; Meijer, D.K. Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo. Antiviral Res., 2004, 63 (3), 197-208.
68. Samanta, M.; Harkins, L.; Klemm, K.; Britt, W.J.; Cobbs, C.S. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J. Urol., 2003, 170 (3), 998-1002.
69. Taher, C.; de Boniface, J.; Mohammad, A.A.; Religa, P.; Hartman, J.; Yaiw, K.C.; Frisell, J.; Rahbar, A.; Söderberg-Nauclér, C. High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. PLoS One, 2013, 8 (2), e56795.
70. Melnick, M.; Mocarski, E.S.; Abichaker, G.; Huang, J.; Jaskoll, T. Cytomegalovirus-induced embryopathology: mouse submandibular salivary gland epithelial-mesenchymal ontogeny as a model. BMC Dev. Biol., 2006, 6, 42.
71. Soroceanu, L.; Cobbs, C.S. Is HCMV a tumor promoter? Virus Res., 2011, 157 (2), 193-203.
72. Johnsen, J.I.; Baryawno, N.; Söderberg-Nauclér, C. Is human cytomegalovirus a target in cancer therapy? Oncotarget, 2011, 2 (12), 1329-1338.
73. Stragliotto, G.; Rahbar, A.; Solberg, N.W.; Lilja, A.; Taher, C.; Orrego, A.; Bjurman, B.; Tammik, C.; Skarman, P.; Peredo, I.; Söderberg- Nauclér, C. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: A randomized, double-blind, hypothesis-generating study. Int. J. Cancer, 2013, 133 (5), 1204-1213.
74. van der Strate, B.W.; Beljaars, L.; Molema, G.; Harmsen, M.C.; Meijer, D.K. Antiviral activities of lactoferrin. Antiviral Res., 2001, 52 (3), 225-239.
75. Berlutti, F.; Pantanella, F.; Natalizi, T.; Frioni, A.; Paesano, R.; Polimeni, A.; Valenti, P. Antiviral properties of lactoferrin - a natural immunity molecule. Molecules, 2011, 16 (8), 6992-7018.
76. Xu, X.X.; Jiang, H.R.; Li, H.B.; Zhang, T.N.; Zhou, Q.; Liu, N. Apoptosis of stomach cancer cell SGC-7901 and regulation of Akt signaling way induced by bovine lactoferrin. J. Dairy Sci., 2010, 93 (6), 2344-2350.
77. Duarte, D.C.; Nicolau, A.; Teixeira, J.A.; Rodrigues, L.R. The effect of bovine milk lactoferrin on human breast cancer cell lines. J. Dairy Sci., 2011, 94 (1), 66-76.
78. Wang, J.; Li, Q.; Ou, Y.; Han, Z.; Li, K.; Wang, P.; Zhou, S. Inhibition of tumor growth by recombinant adenovirus containing human lactoferrin through inducing tumor cell apoptosis in mice bearing EMT6 breast cancer. Arch. Pharm. Res., 2011, 34 (6), 987-995.
79. Li, W.Y.; Li, Q.W.; Han, Z.S.; Jiang, Z.L.; Yang, H.; Li, J.; Zhang, X.B. Growth suppression effects of recombinant adenovirus expressing human lactoferrin on cervical cancer in vitro and in vivo. Cancer Biother. Radiopharm., 2011, 26 (4), 477-483.
80. Li, D.; Sakashita, S.; Morishita, Y.; Kano, J.; Shiba, A.; Sato, T.; Noguchi, M. Binding of lactoferrin to IGBP1 triggers apoptosis in a lung adenocarcinoma cell line. Anticancer Res., 2011, 31 (2), 529-534.
81. Iigo, M.; Kuhara, T.; Ushida, Y.; Sekine, K.; Moore, M.A.; Tsuda, H. Inhibitory effects of bovine lactoferrin on colon carcinoma 26 lung metastasis in mice. Clin. Exp. Metastasis, 1999, 17 (1), 35-40.
82. Norrby, K.; Mattsby-Baltzer, I.; Innocenti, M.; Tuneberg, S. Orally administered bovine lactoferrin systemically inhibits VEGF (165)-mediated angiogenesis in the rat. Int. J. Cancer, 2001, 91 (2), 236-240.
83. Kuhara, T.; Iigo, M.; Itoh, T.; Ushida, Y.; Sekine, K.; Terada, N.; Okamura, H.; Tsuda, H. Orally administered lactoferrin exerts an antimetastatic effect and enhances production of IL-18 in the intestinal epithelium. Nutr. Cancer, 2000, 38 (2), 192-199.
84. Tsuda, H.; Sekine, K.; Takasuka, N.; Toriyama-Baba, H.; Iigo, M. Prevention of colon carcinogenesis and carcinoma metastasis by orally administered bovine lactoferrin in animals. Biofactors, 2000, 12 (1-4), 83-88.
85. Tung, Y.T.; Chen, H.L.; Yen, C.C.; Lee, P.Y.; Tsai, H.C.; Lin, M.F.; Chen, C.M. Bovine lactoferrin inhibits lung cancer growth through suppression of both inflammation and expression of vascular endothelial growth factor. J. Dairy Sci., 2013, 96 (4), 2095-2106.
86. Shimamura, M.; Yamamoto, Y.; Ashino, H.; Oikawa, T.; Hazato, T.; Tsuda, H.; Iigo, M. Bovine lactoferrin inhibits tumor-induced angiogenesis. Int. J. Cancer, 2004, 111 (1), 111-116.
87. Yeom, M.; Park, J.; Lee, B.; Choi, S.Y.; Kim, K.S.; Lee, H.; Hahm, D.H. Lactoferrin inhibits the inflammatory and angiogenic activation of bovine aortic endothelial cells. Inflamm. Res., 2011, 60 (5), 475-482.
88. Artym, J.; Zimecki, M.; Kruzel, M.L. Reconstitution of the cellular immune response by lactoferrin in cyclophosphamide-treated mice is correlated with renewal of T cell compartment. Immunobiology, 2003, 207 (3), 197-205.
89. Artym, J.; Zimecki, M.; Kuryszko, J.; Kruzel, M.L. Lactoferrin accelerates reconstitution of the humoral and cellular immune re sponse during chemotherapy-induced immunosuppression and bone marrow transplant in mice. Stem Cells Dev., 2005, 14 (5), 548-555.
90. Kanwar, J.R.; Palmano, K.P.; Sun, X.; Kanwar, R.K.; Gupta, R.; Haggarty, N.; Rowan, A.; Ram, S.; Krissansen, G.W. 'Ironsaturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. Immunol. Cell Biol., 2008, 86 (3), 277-288.
91. Tomita, M.; Bellamy, W.; Takase, M.; Yamauchi, K.; Wakabayashi, H.; Kawase, K. Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. J. Dairy Sci., 1991, 74 (12), 4137-4142.
92. Bellamy, W.; Takase, M.; Yamauchi, K.; Wakabayashi, H.; Kawase, K.; Tomita, M. Identification of the bactericidal domain of lactoferrin. Biochim. Biophys. Acta, 1992, 1121 (1-2), 130-136.
93. Gifford, J.L.; Hunter, H.N.; Vogel, H.J. Lactoferricin: a lactoferrinderived peptide with antimicrobial, antiviral, antitumor and immunological properties. Cell. Mol. Life Sci., 2005, 62 (22), 2588-2598.
94. Kuwata, H.; Yip, T.T.; Tomita, M.; Hutchens, T.W. Direct evidence of the generation in human stomach of an antimicrobial peptide domain (lactoferricin) from ingested lactoferrin. Biochim. Biophys. Acta, 1998, 1429 (1), 129-141.
95. Kuwata, H.; Yip, T.T.; Yamauchi, K.; Teraguchi, S.; Hayasawa, H.; Tomita, M.; Hutchens, T.W. The survival of ingested lactoferrin in the gastrointestinal tract of adult mice. Biochem. J., 1998, 334 (Pt 2), 321-323.
96. Haug, B.E.; Strom, M.B.; Svendsen, J.S. The medicinal chemistry of short lactoferricin-based antibacterial peptides. Curr. Med. Chem., 2007, 14 (1), 1-18.
97. Schweizer, F. Cationic amphiphilic peptides with cancer-selective toxicity. Eur. J. Pharmacol., 2009, 625 (1-3), 190-194.
98. Utsugi, T.; Schroit, A.J.; Connor, J.; Bucana, C.D.; Fidler, I.J. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. Cancer Res., 1991, 51 (11), 3062-3066.
99. Kim, Y.J.; Varki, A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj. J., 1997, 14 (5), 569-576.
100. Dube, D.H.; Bertozzi, C.R. Glycans in cancer and inflammation - potential for therapeutics and diagnostics. Nat. Rev. Drug Discov., 2005, 4 (6), 477-488.
101. Mader, J.S.; Salsman, J.; Conrad, D.M.; Hoskin, D.W. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines. Mol. Cancer Ther., 2005, 4 (4), 612-624.
102. Eliassen, L.T.; Berge, G.; Leknessund, A.; Wikman, M.; Lindin, I.; Lokke, C.; Ponthan, F.; Johnsen, J.I.; Sveinbjornsson, B.; Kogner, P.; Flaegstad, T.; Rekdal, O. The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int. J. Cancer, 2006, 119 (3), 493-500.
103. Eliassen, L.T.; Berge, G.; Sveinbjornsson, B.; Svendsen, J.S.; Vorland, L.H.; Rekdal, O. Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res., 2002, 22 (5), 2703-2710.
104. Furlong, S.J.; Mader, J.S.; Hoskin, D.W. Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen. Oncol. Rep., 2006, 15 (5), 1385-1390.
105. Mader, J.S.; Smyth, D.; Marshall, J.; Hoskin, D.W. Bovine lactoferricin inhibits basic fibroblast growth factor-and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells. Am. J. Pathol., 2006, 169 (5), 1753-1766.
106. Vogel, H.J.; Schibli, D.J.; Jing, W.; Lohmeier-Vogel, E.M.; Epand, R.F.; Epand, R.M. Towards a structure-function analysis of bovine lactoferricin and related tryptophan-and arginine-containing peptides. Biochem. Cell Biol., 2002, 80 (1), 49-63.
107. Yang, N.; Strom, M.B.; Mekonnen, S.M.; Svendsen, J.S.; Rekdal, O. The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells. J. Pept. Sci., 2004, 10 (1), 37-46.
108. Eliassen, L.T.; Haug, B.E.; Berge, G.; Rekdal, O. Enhanced antitumour activity of 15-residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilic N-terminal modifications. J. Pept. Sci., 2003, 9 (8), 510-517.
109. Fadnes, B.; Rekdal, O.; Uhlin-Hansen, L. The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells. BMC Cancer, 2009, 9, 183.
110. Fadnes, B.; Uhlin-Hansen, L.; Lindin, I.; Rekdal, O. Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells. BMC Cancer, 2011, 11, 116.
111. Berge, G.; Eliassen, L.T.; Camilio, K.A.; Bartnes, K.; Sveinbjornsson, B.; Rekdal, O. Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide. Cancer Immunol. Immunother., 2010, 59 (8), 1285-1294.
112. Loukas, S.; Varoucha, D.; Zioudrou, C.; Streaty, R.A.; Klee, W.A. Opioid activities and structures of alpha-casein-derived exorphins. Biochemistry, 1983, 22 (19), 4567-4573.
113. Mierke, D.F.; Nossner, G.; Schiller, P.W.; Goodman, M. Morphiceptin analogs containing 2-aminocyclopentane carboxylic acid as a peptidomimetic for proline. Int. J. Pept. Protein Res., 1990, 35 (1), 35-45.
114. Kampa, M.; Loukas, S.; Hatzoglou, A.; Martin, P.; Martin, P.M.; Castanas, E. Identification of a novel opioid peptide (Tyr-Val-Pro-Phe-Pro) derived from human alpha S1 casein (alpha S1-casomorphin, and alpha S1-casomorphin amide). Biochem. J., 1996, 319 (Pt 3), 903-908.
115. Parker, F.; Migliore-Samour, D.; Floc'h, F.; Zerial, A.; Werner, G.H.; Jolles, J.; Casaretto, M.; Zahn, H.; Jolles, P. Immunostimulating hexapeptide from human casein: amino acid sequence, synthesis and biological properties. Eur. J. Biochem., 1984, 145 (3), 677-682.
116. Rysz, J.; Redlinski, A.; Mudyna, J.; Luciak, M.; Kaminski, Z.J. Synthesis and immunomodulatory activity of novel analogues of human beta-casein fragment [54-59]. Acta Pol. Pharm., 2000, 57 Suppl, 11-14.
117. Sharma, P.; Singh, N.; Garg, R.; Haq, W.; Dube, A. Efficacy of human beta-casein fragment (54-59) and its synthetic analogue compound 89/215 against Leishmania donovani in hamsters. Peptides, 2004, 25 (11), 1873-1881.
118. Thakur, D.; Saxena, R.; Singh, V.; Haq, W.; Katti, S.B.; Singh, B.N.; Tripathi, R.K. Human beta casein fragment (54-59) modulates M. bovis BCG survival and basic transcription factor 3 (BTF3) expression in THP-1 cell line. PLoS One, 2012, 7 (9), e45905.
119. Perpetuo, E.A.; Juliano, L.; Lebrun, I. Biochemical and pharmacological aspects of two bradykinin-potentiating peptides obtained from tryptic hydrolysis of casein. J. Protein Chem., 2003, 22 (7-8), 601-606.
120. Lebrun, I.; Cavallaro, V.; Juliano, L.; Juliano, M.A.; de Sousa e Silva, M.C. Effects of 'casoparan', a peptide isolated from casein hydrolysates with mastoparan-like properties. Mediators Inflamm., 2004, 13 (4), 263-268.
121. R. Avezedo, A.F., A. Auada, K., Pasqualoto, R. Marques-Porto, D. Maria and I. Lebrun. Antitumor Effect of Cationic INKKI Peptide from Bovine α-Casein on Melanoma B16F10. J. Cancer Ther., 2012, 3 (4), 237-244.
122. Otani, H.; Suzuki, H. Isolation and characterization of cytotoxic small peptides, α-casecidins, from bovine α s1-casein digested with bovine trypsin. Animal Sci. J., 2003, 74 (5), 427-435.
123. Matin, M.A.; Otani, H. Cytotoxic and antibacterial activities of chemically synthesized kappa-casecidin and its partial peptide fragments. J. Dairy Res., 2002, 69 (2), 329-334.
124. Svanborg, C.; Agerstam, H.; Aronson, A.; Bjerkvig, R.; Duringer, C.; Fischer, W.; Gustafsson, L.; Hallgren, O.; Leijonhuvud, I.; Linse, S.; Mossberg, A.K.; Nilsson, H.; Pettersson, J.; Svensson, M. HAMLET kills tumor cells by an apoptosis-like mechanism - cellular, molecular, and therapeutic aspects. Adv. Cancer Res., 2003, 88, 1-29.
125. Fischer, W.; Gustafsson, L.; Mossberg, A.K.; Gronli, J.; Mork, S.; Bjerkvig, R.; Svanborg, C. Human alpha-lactalbumin made lethal to tumor cells (HAMLET) kills human glioblastoma cells in brain xenografts by an apoptosis-like mechanism and prolongs survival. Cancer Res., 2004, 64 (6), 2105-2112.
126. Hakansson, A.P.; Roche-Hakansson, H.; Mossberg, A.K.; Svanborg, C. Apoptosis-like death in bacteria induced by HAMLET, a human milk lipid-protein complex. PLoS One, 2011, 6 (3), e17717.
127. Hakansson, A.; Svensson, M.; Mossberg, A.K.; Sabharwal, H.; Linse, S.; Lazou, I.; Lonnerdal, B.; Svanborg, C. A folding variant of alpha-lactalbumin with bactericidal activity against Streptococcus pneumoniae. Mol. Microbiol., 2000, 35 (3), 589-600.
128. Svensson, M.; Fast, J.; Mossberg, A.K.; Duringer, C.; Gustafsson, L.; Hallgren, O.; Brooks, C.L.; Berliner, L.; Linse, S.; Svanborg, C. Alpha-lactalbumin unfolding is not sufficient to cause apoptosis, but is required for the conversion to HAMLET (human alphalactalbumin made lethal to tumor cells). Protein Sci., 2003, 12 (12), 2794-2804.
129. Svensson, M.; Mossberg, A.K.; Pettersson, J.; Linse, S.; Svanborg, C. Lipids as cofactors in protein folding: stereo-specific lipidprotein interactions are required to form HAMLET (human alphalactalbumin made lethal to tumor cells). Protein Sci., 2003, 12 (12), 2805-2814.
130. Gustafsson, L.; Hallgren, O.; Mossberg, A.K.; Pettersson, J.; Fischer, W.; Aronsson, A.; Svanborg, C. HAMLET kills tumor cells by apoptosis: structure, cellular mechanisms, and therapy. J. Nutr., 2005, 135 (5), 1299-1303.
131. T, J.M.P. In Milk Protein. Hurley, W.L., Ed.; InTech, 2012.
132. Duringer, C.; Hamiche, A.; Gustafsson, L.; Kimura, H.; Svanborg, C. HAMLET interacts with histones and chromatin in tumor cell nuclei. J. Biol. Chem., 2003, 278 (43), 42131-42135.
133. Hallgren, O.; Gustafsson, L.; Irjala, H.; Selivanova, G.; Orrenius, S.; Svanborg, C. HAMLET triggers apoptosis but tumor cell death is independent of caspases, Bcl-2 and p53. Apoptosis, 2006, 11 (2), 221-233.
134. Kohler, C.; Gogvadze, V.; Hakansson, A.; Svanborg, C.; Orrenius, S.; Zhivotovsky, B. A folding variant of human alpha-lactalbumin induces mitochondrial permeability transition in isolated mitochondria. Eur. J. Biochem., 2001, 268 (1), 186-191.
135. Aits, S.; Gustafsson, L.; Hallgren, O.; Brest, P.; Gustafsson, M.; Trulsson, M.; Mossberg, A.K.; Simon, H.U.; Mograbi, B.; Svanborg, C. HAMLET (human alpha-lactalbumin made lethal to tumor cells) triggers autophagic tumor cell death. Int. J. Cancer, 2009, 124 (5), 1008-1019.
136. Trulsson, M.; Yu, H.; Gisselsson, L.; Chao, Y.; Urbano, A.; Aits, S.; Mossberg, A.K.; Svanborg, C. HAMLET binding to alphaactinin facilitates tumor cell detachment. PLoS One, 2011, 6 (3), e17179.
137. Gustafsson, L.; Aits, S.; Onnerfjord, P.; Trulsson, M.; Storm, P.; Svanborg, C. Changes in proteasome structure and function caused by HAMLET in tumor cells. PLoS One, 2009, 4 (4), e5229.
138. Puthia, M.; Storm, P.; Nadeem, A.; Hsiung, S.; Svanborg, C. Prevention and treatment of colon cancer by peroral administration of HAMLET (human alpha-lactalbumin made lethal to tumour cells). Gut, 2014, 63 (1), 131-142.
139. Pettersson, J.; Mossberg, A.K.; Svanborg, C. alpha-Lactalbumin species variation, HAMLET formation, and tumor cell death. Biochem. Biophys. Res. Commun., 2006, 345 (1), 260-270.
140. Xiao, Z.; Mak, A.; Koch, K.; Moore, R.B. A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells in vitro and inhibits tumour growth in an orthotopic rat bladder tumour model. BJU Int., 2013, 112 (2), E201-E210.
141. Rammer, P.; Groth-Pedersen, L.; Kirkegaard, T.; Daugaard, M.; Rytter, A.; Szyniarowski, P.; Hoyer-Hansen, M.; Povlsen, L.K.; Nylandsted, J.; Larsen, J.E.; Jaattela, M. BAMLET activates a lysosomal cell death program in cancer cells. Mol. Cancer Ther., 2010, 9 (1), 24-32.
142. Tolin, S.; De Franceschi, G.; Spolaore, B.; Frare, E.; Canton, M.; Polverino de Laureto, P.; Fontana, A. The oleic acid complexes of proteolytic fragments of alpha-lactalbumin display apoptotic activity. FEBS J., 2010, 277 (1), 163-173.
143. Pettersson-Kastberg, J.; Mossberg, A.K.; Trulsson, M.; Yong, Y.J.; Min, S.; Lim, Y.; O'Brien, J.E.; Svanborg, C.; Mok, K.H. alpha-Lactalbumin, engineered to be nonnative and inactive, kills tumor cells when in complex with oleic acid: a new biological function resulting from partial unfolding. J. Mol. Biol., 2009, 394 (5), 994-1010.
144. Ho, C.S.J.; Rydstrom, A.; Manimekalai, M.S.; Svanborg, C.; Gruber, G. Low resolution solution structure of HAMLET and the importance of its alpha-domains in tumoricidal activity. PLoS One, 2012, 7 (12), e53051.
145. Brinkmann, C.R.; Thiel, S.; Otzen, D.E. Protein-fatty acid complexes: biochemistry, biophysics and function. FEBS J., 2013, 280 (8), 1733-1749.
146. Brinkmann, C.R.; Thiel, S.; Larsen, M.K.; Petersen, T.E.; Jensenius, J.C.; Heegaard, C.W. Preparation and comparison of cytotoxic complexes formed between oleic acid and either bovine or human alpha-lactalbumin. J. Dairy Sci., 2011, 94 (5), 2159-2170.
147. Permyakov, S.E.; Knyazeva, E.L.; Leonteva, M.V.; Fadeev, R.S.; Chekanov, A.V.; Zhadan, A.P.; Hakansson, A.P.; Akatov, V.S.; Permyakov, E.A. A novel method for preparation of HAMLET-like protein complexes. Biochimie, 2011, 93 (9), 1495-1501.
148. Liskova, K.; Kelly, A.L.; O'Brien, N.; Brodkorb, A. Effect of denaturation of alpha-lactalbumin on the formation of BAMLET (bovine alpha-lactalbumin made lethal to tumor cells). J. Agric. Food Chem., 2010, 58 (7), 4421-4427.
149. Permyakov, S.E.; Knyazeva, E.L.; Khasanova, L.M.; Fadeev, R.S.; Zhadan, A.P.; Roche-Hakansson, H.; Hakansson, A.P.; Akatov, V.S.; Permyakov, E.A. Oleic acid is a key cytotoxic component of HAMLET-like complexes. Biol. Chem., 2012, 393 (1-2), 85-92.
150. Masuda, C.; Wanibuchi, H.; Sekine, K.; Yano, Y.; Otani, S.; Kishimoto, T.; Tsuda, H.; Fukushima, S. Chemopreventive effects of bovine lactoferrin on N-butyl-N-(4-hydroxybutyl)nitrosamineinduced rat bladder carcinogenesis. Jpn. J. Cancer Res., 2000, 91 (6), 582-588.
151. Tanaka, T.; Kawabata, K.; Kohno, H.; Honjo, S.; Murakami, M.; Ota, T.; Tsuda, H. Chemopreventive effect of bovine lactoferrin on 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats. Jpn. J. Cancer Res., 2000, 91 (1), 25-33.
152. Ushida, Y.; Sekine, K.; Kuhara, T.; Takasuka, N.; Iigo, M.; Maeda, M.; Tsuda, H. Possible chemopreventive effects of bovine lactoferrin on esophagus and lung carcinogenesis in the rat. Jpn. J. Cancer Res., 1999, 90 (3), 262-267.
153. Kozu, T.; Iinuma, G.; Ohashi, Y.; Saito, Y.; Akasu, T.; Saito, D.; Alexander, D.B.; Iigo, M.; Kakizoe, T.; Tsuda, H. Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial. Cancer Prev. Res. (Phila.), 2009, 2 (11), 975-983.
154. Digumarti, R.; Wang, Y.; Raman, G.; Doval, D.C.; Advani, S.H.; Julka, P.K.; Parikh, P.M.; Patil, S.; Nag, S.; Madhavan, J.; Bapna, A.; Ranade, A.A.; Varadhachary, A.; Malik, R. A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J. Thorac. Oncol., 2011, 6 (6), 1098-1103.
155. Guntupalli, K.; Dean, N.; Morris, P.E.; Bandi, V.; Margolis, B.; Rivers, E.; Levy, M.; Lodato, R.F.; Ismail, P.M.; Reese, A.; Schaumberg, J.P.; Malik, R.; Dellinger, R.P.; Group, T.L.-I. A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Crit. Care Med., 2013, 41 (3), 706-716.
156. ClinicalTrials.gov NCT01058616. Dose-escalation Study of LTX-315 in Patients with a Transdermal Accessible Tumour. http://clinicaltrials.gov/show/ NCT01058616
157. ClinicalTrials.gov NCT01223209. A study, combination, immunologic study of LTX-315 as adjunct to GV1001 in patients following curative surgery for carcinoma. http://clinicaltrials.gov/show/NCT01223209
158. NatImmune Initiates Phase IIb Clinical Study with BAMLET Topical Gel for Skin Warts in Transplant Patients http:// www.evaluatepharma.com/Universal/View. aspx?type=Story& id=170160
159. Azoulay, E.; Soares, M.; Darmon, M.; Benoit, D.; Pastores, S.; Afessa, B. Intensive care of the cancer patient: recent achievements and remaining challenges. Ann. Intensive Care, 2011, 1 (1), 5.
160. Singal, P.K.; Li, T.; Kumar, D.; Danelisen, I.; Iliskovic, N. Adriamycin-induced heart failure: mechanism and modulation. Mol. Cell. Biochem., 2000, 207 (1-2), 77-86.
161. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 2004, 56 (2), 185-229.
162. Razzaque, M.S. Cisplatin nephropathy: is cytotoxicity avoidable? Nephrol. Dial. Transplant., 2007, 22 (8), 2112-2116.
163. Fortunati, N.; Manti, R.; Birocco, N.; Pugliese, M.; Brignardello, E.; Ciuffreda, L.; Catalano, M.G.; Aragno, M.; Boccuzzi, G. Proinflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients. Oncol. Rep., 2007, 18 (6), 1521-1527.
164. Laviano, A.; Meguid, M.M.; Preziosa, I.; Rossi Fanelli, F. Oxidative stress and wasting in cancer. Curr. Opin. Clin. Nutr. Metab. Care, 2007, 10 (4), 449-456.
165. Tozer, R.G.; Tai, P.; Falconer, W.; Ducruet, T.; Karabadjian, A.; Bounous, G.; Molson, J.H.; Droge, W. Cysteine-rich protein reverses weight loss in lung cancer patients receiving chemotherapy or radiotherapy. Antioxid. Redox. Signal., 2008, 10 (2), 395-402.
166. ClinicalTrials.gov NCT01766804. Effect of bovine colostrum on toxicity and inflammatory responses (CALL). http://clinicaltrials.gov/show/NCT01766804
167. Bagley, K. Sweet relief. The Scientist, 2010, 24 (3), 1.
168. Sun, X.; Zhang, J.; Gupta, R.; Macgibbon, A.K.; Kuhn-Sherlock, B.; Krissansen, G.W. Dairy milk fat augments paclitaxel therapy to suppress tumour metastasis in mice, and protects against the side-effects of chemotherapy. Clin. Exp. Metastasis, 2011, 28 (7), 675-688.
169. Samir, P.; Link, A.J. Analyzing the cryptome: uncovering secret sequences. AAPS J., 2011, 13 (2), 152-158.
170. Dahl, D.; Wojtal, G.G.; Breslow, M.J.; Holl, R.; Huguez, D.; Stone, D.; Korpi, G. The high cost of low-acuity ICU outliers. J. Healthc. Manag., 2012, 57 (6), 421-433; discussion 434.